Form 4 Filing for Laura Brege

Laura Brege, a director at ACADIA PHARMACEUTICALS INC, acquired 8,107 shares of Common Stock and was granted 16,004 Director Stock Options and 9,311 Restricted Stock Units on May 29, 2026. The acquisition of Common Stock was a non-derivative transaction. The Restricted Stock Units were vested and disposed of, with each unit representing a contingent right to one share of common stock. The stock options have an exercise price of $21.66 and vest quarterly over one year. The remaining Restricted Stock Units will vest on the earlier of one year from the grant date or the next annual meeting of stockholders, with deferred receipt options available.